Posts

Capricor surges on plan to amend DMD filing after adcom setback

FDA Committee Rejects Capricor's Duchenne Cell Therapy Amid Statistical Dispute

Sarepta Halts US Shipments of Duchenne Therapy Elevidys After FDA Pressure

Avidity's Del-zota Shows Promise in Duchenne Muscular Dystrophy Treatment

Entrada given go-ahead to test DMD therapy after two-year hold

Sarepta Therapeutics Reports Encouraging Two-Year Data for ELEVIDYS in Duchenne Muscular Dystrophy, Projecting $1 Billion in Sales